BR112023014723A2 - Compostos moduladores de gcn2 e usos dos mesmos - Google Patents
Compostos moduladores de gcn2 e usos dos mesmosInfo
- Publication number
- BR112023014723A2 BR112023014723A2 BR112023014723A BR112023014723A BR112023014723A2 BR 112023014723 A2 BR112023014723 A2 BR 112023014723A2 BR 112023014723 A BR112023014723 A BR 112023014723A BR 112023014723 A BR112023014723 A BR 112023014723A BR 112023014723 A2 BR112023014723 A2 BR 112023014723A2
- Authority
- BR
- Brazil
- Prior art keywords
- gcn2
- modulator compounds
- compounds
- modulating
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
- Holo Graphy (AREA)
- Liquid Crystal Substances (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163140314P | 2021-01-22 | 2021-01-22 | |
| PCT/US2022/013383 WO2022159746A1 (en) | 2021-01-22 | 2022-01-21 | Gcn2 modulating compounds and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023014723A2 true BR112023014723A2 (pt) | 2023-10-03 |
Family
ID=80446635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023014723A BR112023014723A2 (pt) | 2021-01-22 | 2022-01-21 | Compostos moduladores de gcn2 e usos dos mesmos |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20240083897A1 (https=) |
| EP (1) | EP4281182A1 (https=) |
| JP (1) | JP2024504364A (https=) |
| KR (1) | KR20240021143A (https=) |
| CN (1) | CN117203206A (https=) |
| AU (1) | AU2022210760A1 (https=) |
| BR (1) | BR112023014723A2 (https=) |
| CA (1) | CA3209124A1 (https=) |
| CO (1) | CO2023010940A2 (https=) |
| CR (1) | CR20230408A (https=) |
| IL (1) | IL304611A (https=) |
| MX (1) | MX2023008589A (https=) |
| PE (1) | PE20240691A1 (https=) |
| WO (1) | WO2022159746A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202008749D0 (en) | 2020-06-09 | 2020-07-22 | Ip2Ipo Innovations Ltd | Novel compounds |
| WO2023230567A1 (en) * | 2022-05-25 | 2023-11-30 | Hibercell, Inc. | Gcn2 modulator for treating cancer |
| WO2024077092A1 (en) * | 2022-10-04 | 2024-04-11 | Hibercell, Inc. | Gcn2 inhibitor for treating metastases |
| IL322199A (en) * | 2023-01-20 | 2025-09-01 | Hibercell Inc | Crystalline forms of 6-(3-((5-chloro-2-methoxypyridine)-3-sulfonamido)-6,2-difluorophenyl)-N-methylimidazo[1, 5-A]pyrazine-1-carboxamide and methods of use are |
| WO2025122985A1 (en) * | 2023-12-08 | 2025-06-12 | Hibercell, Inc. | Methods of treating acute myeloid leukemia using combinations of gcn2 modulators, venetoclax, and azacitidine |
| WO2025137710A1 (en) * | 2023-12-22 | 2025-06-26 | Hibercell, Inc. | Methods of treating cancer using combinations of gcn2 modulators and belzutifan |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004279427B2 (en) * | 2003-10-08 | 2008-07-03 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| ES2422263T3 (es) * | 2008-12-19 | 2013-09-10 | Nerviano Medical Sciences Srl | Pirazoles bicíclicos como inhibidores de la proteinquinasa |
| HRP20241768T1 (hr) * | 2016-08-10 | 2025-02-28 | Takeda Pharmaceutical Company Limited | Heterociklički spoj |
| JP7229257B2 (ja) * | 2018-01-29 | 2023-02-28 | メルク パテント ゲーエムベーハー | Ｇｃｎ２阻害剤およびその使用 |
| US20220388964A1 (en) * | 2019-04-12 | 2022-12-08 | Hibercell, Inc. | (aza)indazolyl-aryl sulfonamide and related compounds and their use in treating medical conditions |
| JP2023514328A (ja) * | 2020-02-17 | 2023-04-05 | アレスタ・セラピューティクス・ベスローテン・フェンノートシャップ | Ｇｃｎ２モジュレーター化合物 |
-
2022
- 2022-01-21 BR BR112023014723A patent/BR112023014723A2/pt unknown
- 2022-01-21 KR KR1020237028260A patent/KR20240021143A/ko active Pending
- 2022-01-21 CA CA3209124A patent/CA3209124A1/en active Pending
- 2022-01-21 PE PE2023002158A patent/PE20240691A1/es unknown
- 2022-01-21 EP EP22704111.8A patent/EP4281182A1/en active Pending
- 2022-01-21 US US18/262,493 patent/US20240083897A1/en active Pending
- 2022-01-21 WO PCT/US2022/013383 patent/WO2022159746A1/en not_active Ceased
- 2022-01-21 MX MX2023008589A patent/MX2023008589A/es unknown
- 2022-01-21 JP JP2023544292A patent/JP2024504364A/ja active Pending
- 2022-01-21 CR CR20230408A patent/CR20230408A/es unknown
- 2022-01-21 AU AU2022210760A patent/AU2022210760A1/en active Pending
- 2022-01-21 CN CN202280022926.3A patent/CN117203206A/zh active Pending
-
2023
- 2023-07-20 IL IL304611A patent/IL304611A/en unknown
- 2023-08-22 CO CONC2023/0010940A patent/CO2023010940A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024504364A (ja) | 2024-01-31 |
| KR20240021143A (ko) | 2024-02-16 |
| CA3209124A1 (en) | 2022-07-28 |
| CO2023010940A2 (es) | 2023-12-11 |
| CN117203206A (zh) | 2023-12-08 |
| US20240083897A1 (en) | 2024-03-14 |
| CR20230408A (es) | 2024-05-07 |
| EP4281182A1 (en) | 2023-11-29 |
| IL304611A (en) | 2023-09-01 |
| WO2022159746A1 (en) | 2022-07-28 |
| AU2022210760A1 (en) | 2023-09-07 |
| MX2023008589A (es) | 2023-08-09 |
| PE20240691A1 (es) | 2024-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023014723A2 (pt) | Compostos moduladores de gcn2 e usos dos mesmos | |
| BR112022004802A2 (pt) | Moduladores de il-17a e usos dos mesmos | |
| BR112021021754A2 (pt) | Cicloalquilas substituídas como moduladoras da via de estresse integrada | |
| PH12020551184A1 (en) | Biaryl derivative, preparation method thereof and pharmaceutical application thereof | |
| MX2025005941A (es) | Moduladores de la actividad tnf-\03b1 | |
| ECSP21086429A (es) | Moduladores de la vía integrada del estrés | |
| MX2020011234A (es) | Moduladores de receptor similar al dominio de oligomerizacion de union a nucleotidos que contiene dominio de pirina 3 (nlrp3). | |
| WO2020163823A3 (en) | Therapeutic agents and methods of treatment | |
| BR112017020895A2 (pt) | inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer | |
| MX2023009682A (es) | Inhibidores de tyk2 y sus usos. | |
| NZ757081A (en) | Somatostatin modulators and uses thereof | |
| CY1125354T1 (el) | Διαδικασια παρασκευης ρυθμιστων σωματοστατινης | |
| BR112022010082A2 (pt) | Composto de fórmula estrutural i ou sal do mesmo, composição farmacêutica, uso do composto e uso da composição farmacêutica | |
| MX2022010693A (es) | Compuestos, composiciones y metodos para inhibidores de la proteina quinasa que interactua con el receptor i para el tratamiento de enfermedades. | |
| JOP20250149A1 (ar) | مثبطات malt1 | |
| BR112022008287A2 (pt) | Métodos de tratamento usando um modulador de mtorc1 | |
| WO2022175746A8 (en) | Tyk2 inhibitors and uses thereof | |
| MX2025003515A (es) | Moduladores de akt1 | |
| BRPI0516883A (pt) | compostos e métodos para modulação da atividade de trombopoietina | |
| BR112022003768A2 (pt) | Compostos inibidores de perk | |
| MX2023005913A (es) | Derivados de bencenosulfonamida y usos de los mismos. | |
| WO2020231739A3 (en) | Compounds and methods for treating cancer | |
| WO2019236765A8 (en) | Acylated catechin polyphenols and methods of their use for the treatment of cancer | |
| MX2024004416A (es) | Nuevos moduladores de ehmt1 y ehmt2 y uso terapéutico de estos. | |
| AU2020264106A8 (en) | Small molecule bromodomain inhibitors and uses thereof |